MRI-efficacy of Abatacept in patients with rheumatoid arthritis [MIYAKO study]

MRI-efficacy of Abatacept in patients with rheumatoid arthritis [MIYAKO study] - MRI-efficacy of Abatacept in patients with rheumatoid arthritis [MIYAKO study]

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000016613

Enrollment

Registered

2015-02-25

Start date

2011-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with written informed consent for participating in the study 2. Patients diagnosed as having rheumatoid arthritis according to ACR 1987 revised classification criteria for rheumatoid arthritis or ACR/EULAR 2010 revised classification criteria for rheumatoid arthritis 3. Glucocorticoid use should be under 10 mg/day

Exclusion criteria

Exclusion criteria: Patients with the reasons for inadequate to participate in this study, judeged by attending rheumatologist

Design outcomes

Primary

Measure	Time frame
Assessment of efficacy of abatacept : 48 weeks follow-up with MRI	—

Countries

Japan

Contacts

Public ContactYuji Kukida

Graduate School of Medical Science, Kyoto Prefectural University of Medicine Inflammation and Immunology

y-kukida@koto.kpu-m.ac.jp075-251-5505

Outcome results